Skip to content
Menu

Barclays Maintains Overweight on Sutro Biopharma, Raises Price Target to $57

Benzinga Newsdesk 6 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Barclays analyst Lukas Shumway maintains Sutro Biopharma (NASDAQ:STRO) with a Overweight and raises the price target from $56 to $57.

Barclays analyst Lukas Shumway maintains Sutro Biopharma (NASDAQ:STRO) with a Overweight and raises the price target from $56 to $57.

Read at benzinga.com